2-Methylbutyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate, 95.0%, 1g

6-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole, 95.0%, 5g

3-Fluoro-2-hydroxypyridine, 95.0%, 5g

1-(3-Methoxyphenyl)-N-methylmethanamine, 97.0%, 10g

Benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methyl-4-piperidinyl)-, 97%, 10mg

2-Chloro-4-(cyclopropylmethyl)-1-fluorobenzene, 98%, 500mg

2-[(3-chlorobenzyl)thio]ethanamine, 95.0%, 5g

N-Boc-Morpholine-2-carboxylic acid, 95.0%, 100g

2-Methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 95+%, 10g

GC capillary column ROTI®Cap-1, 30 m, 0.32 mm, 0.25 µm, 1 Piece(s)

(2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid, 97.0%, 25mg

2-Bromo-3-fluorobenzaldehyde, 97.0%, 1g

Trifluoroacetic acid hydrazide, 95.0%, 25g